Klinik für Strahlentherapie und Onkologie

Prof. Dr. rer. nat. Franz Rödel

Publikationsverzeichnis

Inhalte auf dieser Seite: Auswahl der wichtigsten Publikationen

Auswahl der wichtigsten Publikationen

  1. Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rödel C. Survivin As a Radio-Resistance Factor, and Prognostic and Therapeutic Target for Radiotherapy in Rectal Cancer. Cancer Res 2005;65:4881-87
  2. Sprenger T, Rödel F, Beissbarth T, Conradi L, Rothe  H, Homayounfar K, Wolff H, Ghadimi M, Yildirim M, Becker H, Rödel C, Liersch T. Failure of down-regulation of Survivin expression following neoadjuvant chemoradiation in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 2011;17:1623-31. Geteilte Erstautorenschaft.
  3. Gaca S, Reichert S, Multhoff G, Hehlgans S, Botzler K, Rödel C, Kreuter J, Rödel F. Targeting and radiosensitization of glioblastoma cells by cmHsp70.1-antibody coated and survivin miRNA plasmid-loaded nanoparticles. J Control Release 2013;172:201-206.
  4. Rödel F, Wieland U, Fraunholz I, Kitz J, Rave-Fränk M, Wolff HA, Weiss C, Wirtz R, Balermpas P, Fokas E, Rödel C. Human papillomavirus load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Int J Cancer 2015; 136:278–288.
  5. Helmke C, Raab M, Rödel F, Matthess Y, Oellerich T, Mandal R, SanHaji M, Urlaub H, Rödel C, Becker S and Strebhardt K. Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of Caspase-8. Cell Res 2016;26:914-34.
  6. Balermpas P, Martin D, Wieland U, Rave-Fränk M, Strebhardt K, Rödel C, Fokas E, Rödel F. Human papilloma virus load and PD-1/PD-L1, CD8 and FOXP3 in anal cancer patients treated with chemo radiotherapy: Rationale for immunotherapy. Oncoimmunology 2017;6:e1288331.
  7. Rödel F, Martin D, Balermpas P, Wieland U, Winkelmann R, Riekmann T, Falk S, Rödel C, Fokas E. Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. Biochim Biophys Acta Rev Cancer  2018;1871:126-137.
  8. Schulz M, Michels B, Niesel K, Stein S, Farin H, Rödel F, Sevenich L. Cellular and molecular changes of brain metastases-associated myeloid cells during disease progression and therapeutic response iScience 2020;23:101178
  9. Güllülü Ö, Hehlgans S, Mayer BE, Gößner I, Petraki C, Hoffmann M, Dombrowsky MJ, Kunzmann P, Hamacher K, Strebhardt K, Fokas E, Rödel C, Münch C, Rödel F. A spatial and functional interaction of a heterotetramer Survivin-DNA-PKcs complex in DNA damage response. Cancer Res 2021;81:2304-2317.
  10. Niesel K, Schulz M, Anthes J, Alekseeva T, Macas J, Salamero-Boix A, Möckl A, Oberwahrenbrock T, Lolies M, Stein S, Plate KH, Reiss Y, Rödel F, Sevenich L. The immune suppressive microenvironment affects efficacy of radio-immunotherapy in brain metastasis. EMBO Mol Med 2021:13:e13412.
  11. Nicolas A, Pesic M, Engel E, Paul K. Ziegler P, Diefenhardt M, Kennel KB, Büttner F, Conche C, Petrocelli V, Elwakeel E, Weigert A, Zinoveva A, Fleischmann M, Häupl B, Karakütük C, Bohnenberger H, Mosa M, Kaderali L, Gaedcke J, Ghadimi M, Rödel F, Arkan MC, Oellerich T, Rödel C, Fokas E, Greten FR. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell 2022;40:1-17.

Originalarbeiten

  1. Beuscher HU, Rödel F, Röllinghoff M. Inhibition of TNFa in murine yersiniosis. Lymphokine and Cytokine Research 1993;12:370-74.
  2. Rausch UP, Jordan M, Rödel F, Aigner T, Otterness IG, Beuscher N, Röllinghoff M, Beuscher HU. Transcriptional and translational regulation of IL-1a and IL-1ß account for the control of IL-1 in experimental yersiniosis. Cytokine 1994;6:504-11.
  3. Beuscher HU, Rödel F, Forsberg A, Röllinghoff M. Bacterial evasion from host immune defence: Yersinia enterocolitica encodes a suppresssor for tumor necrosis factor (TNF) expression. Infect Immun 1995;63:1270-77.
  4. Rödel C, Grabenbauer GG, Rödel F, Birkenhake S, Kühn R, Martus P, Zörcher T, Fürsich D, Papadopoulos T, Dunst J, Schrott KM, Sauer R. Apoptosis, p53, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radio- chemotherapy and sucessful bladder preservation. Int J Radiat Oncol Biol Phys 2000;46:1213-21.
  5. Grabenbauer GG, Mühlfriedel C, Rödel F, Niedobitek G, Hornung J, Rödel C, Martus P, Iro H, Kirchner T, Steininger H, Sauer R, Weidenbecher M, Distel L. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients with high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1041-50.
  6. Schultze-Mosgau S, Rödel F, Keilholz L, Grabenbauer GG, Wiltfang J, Radespiel-Tröger M, Sauer R, Neukam FW. Vascularization of free myocutaneous gracilis flaps in replacement transplantation after preoperative radiotherapy: an experimental study. Strahlenther Onkol 2000;176:498-505.
  7. Schultze-Mosgau S, Keilholz L, Rödel F, Labahn D, Neukam FW. Experimental model for transplantation of modified free myocutaneous gracilis flap in irradiated neck regions in rats. Int J Oral Maxillofac Surg 2001;30:63-69.
  8. Rödel C, Grabenbauer GG, Papadopoulos T, Bigalke M, Günther K, Schick C, Peters A, Sauer R, Rödel F. Apoptosis as a cellular predictor for histopathological response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2002;52:294-303.
  9. Hildebrandt G, Maggiorella L, Rödel F, Rödel V, Willis D, Trott KR. Mononuclear cell adhesion and cell adhesion molecule liberation after X-irradiation of activated endothelial cells in vitro. Int J Radiat Biol 2002;78:315-25.
  10. Schultze-Mosgau S, Rödel F, Keilholz L, Radespiel-Tröger M, Wörl J, Grabenbauer GG, Neukam FW. Vascularisation of the area between free grafts and irradiated graft beds in the neck of rats. Br J Oral Maxillofac Surg 2002;40:37-44.
  11. Schultze-Mosgau S, Wehrhan F, Grabenbauer GG, Amann K, Radespiel-Tröger M, Neukam FW, Rödel F. Transforming Growth Factor b1 and b2 (TGF-b1/TGF-b2) profile changes in previously irradiated free flap beds. Head Neck 2002; 24:33-41.
  12. Schultze-Mosgau S, Wehrhahn F, Grabenbauer GG, Radespiel-Tröger M, Wiltfang J, Ries J, Neukam FW, Rödel F. Vascularisation in the transition area between free grafted soft tissues and preirradiated graft bed tissues following preoperative radiotherapy  in the head and neck region. Head Neck 2002;24:42-51.
  13. Rödel F, Kley N, Beuscher HU, Hildebrandt G, Kern P, Keilholz L, Herrmann M, Sauer R. Antiinflammatory effect of low dose X-irradiation and the involvement of a TGF-ß1-induced down-regulation of leucocyte/endothelial cell adhesion. Int J Radiat Biol 2002;78:711-19.
  14. Schultze-Mosgau S, Grabenbauer GG, Radespiel-Tröger M, Wiltfang J, Sauer R, Neukam FW, Rödel F. Gefäßstrukturveränderungen von Kopf-Halsgefässen nach präoperativer Radiochemotherapie oder postoperativer Radiotherapie. Strahlenther Onkol 2002;178:299-306.
  15. Yan PS, Efferth T, Chen HL, Lin J, Rödel F, Fuzesi L, Huang THM. Use of CpG islands to identify colerectal tumors with a high degree of concurrrent methylation. Methods 2002;27:162-69.
  16. Rödel F, Hoffmann J, Grabenbauer GG , Papadopoulos T, Günther K,  Schick C , Sauer R, Rödel C. Expression of survivin is associated with apoptosis in rectal cancer and may predict disease free survival after neoadjuvant radiochemotherapy. Strahlenther Onkol 2002;178:426-35.
  17. Schultze-Mosgau S, Wehrhan F, Rödel F, Amann K, Radespiel-Tröger M, Grabenbauer  GG. Transforming growth factor-beta receptor-II up-regulation during wound healing in previously irradiated graft beds in vivo. Wound Rep Reg 2003;11:297-305.
  18. Humeny A, Rödel F, Rödel C, Sauer R, Füzesi L, Becker CM, Efferth T. MDR1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF. Anticancer Research 2003;23:2735-40. geteilte Erstautorenschaft
  19. Günther K, Dimmler A, Rödel F, Reulbach U, Merkel S, Bittdorf B, Matzel K,  Papadopoulos T, Hohenberger W, Sauer R, Rödel C. P27 does not predict histo- pathological response to radiochemotherapy in rectal cancer. J Surg Res 2003;113:179-88.
  20. Schultze-Mosgau S, Wehrhahn F, Amann K, Radespiel-Tröger M, Rödel F, Grabenbauer GG. In-vivo TGFβ3 expression during wound healing in irradiated tissues. Strahlenther Onkol 2003;179:410-16.
  21. Dumitriu I, Rödel F, Beyer T, Gaipl U, Kalden JR, Herrmann M. UV or X-irradiation increase the cytoplasmic accumulation of rhodamine 123 in various cancer cell lines. Strahlenther Onkol 2003;179:564-70.
  22. Rödel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rödel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Survivin as a radioresitance factor. Int J Radiat Oncol Biol Phys 2003;55:1341-47.
  23. Schultze-Mosgau S, Wehrhan F, Rödel F, Amann K, Radespiel-Tröger M, Grabenbauer GG. Transforming growth factor-beta receptor-II up-regulation during wound healing in previously irradiated graft beds in vivo. Wound Rep Reg 2003;11:297-05.
  24. Grabenbauer GG, Suckorada O, Niedobitek G, Rödel F, Iro H, Sauer R, Rödel C, Schultze-Mosgau S, Distel L. Imbalance between proliferation and apoptosis may be responsible for treatment failure after postoperative radiotherapy in squamous cell carcinoma of the oropharynx. Oral Oncol 2003;39:459-69.
  25. Schultze-Mosgau S, Wehrhan F, Rödel F, Amann K, Radespiel-Tröger M, Grabenbauer  GG. Improved free vascular graft survival in an irradiated surgical site following topical application of rVEGF. Int J Radiat Oncol Biol Phys 2003;57:803-12.
  26. Hildebrandt G, Radlingmayr A , Rosenthal S, Rothe R, Jahns J, Hindemith M, Rödel F, Kamprad F. Low-dose radiotherapy (LD-RT) and the modulation of iNOS expression in adjuvant-induced arthritis in rats. Int J Radiat Biol 2003;79:993-1001.
  27. Schultze-Mosgau S, Wehrhan F, Rödel F, Amann K, Radespiel-Tröger M, Kopp J, Grabenbauer GG. Anti-TGFβ1 antibody for modulation of expression of endogenous Transforming Growth Factor beta1 (TGFβ1 ) to prevent fibrosis after plastic surgery in rats. Br J Oral Maxillofac Surg 2004;42:112-19.
  28. Rödel F, Schaller U, Herrmann M, Schultze-Mosgau S, Beuscher HU, Keilholz L, Voll R, Sauer R, Hildebrandt G. Following low dose irradiation the induction of TGF-ß1 and NF-kB parallels a biphasic time course of leukocyte/endothelial cell adhesion. Strahlenther Onkol 2004;180:197-200.
  29. Schultze-Mosgau S, Bläse M, Grabenbauer GG, Wehrhahn F, Kopp J, Amman K,  Rodemann HP, Rödel F. Smad-3 and Smad-7 expression following anti-Transforming Growth Factor beta 1 (TGFβ1)-treatment in irradiated rat tissue. Radiother Oncol 2004;70:249-59.
  30. Rödel F, Hantschel M, Herrmann M, Schultze-Mosgau S, Hildebrandt G, Rödel C, Sauer R, Voll RE. Dose dependent biphasic induction and transcriptinal activity of nuclear factor kappa B (NF-kB) in EA.hy.926 endothelial cells after low dose X irradiation. Int J Radiat Biol 2004;80:115-23.
  31. Wehrhan F, Grabenbauer GG, Rödel F, Amman K, Schultze-Mosgau S. Exogenous modulation of TGFβ1 influences TGFβR-III associated vascularisation during wound healing in irradiated tissue. Strahlenther Onkol 2004;180:526-33.
  32. Lehner B, Bauer J, Rödel F, Grabenbauer GG, Schultze-Mosgau S. Radiation-Induced impairment of osseous healing with vascularized bone transfer: Experimental Model using a pedicled tibia flap in rats. Int J Oral Maxillofac Surg 2004;33:486-92.
  33. Matzer SP, Rödel F, Strieter RM, Röllinghoff M, Beuscher HU. Constitutive expression of CXCL2/MIP-2 is restricted to a Gr-1high, CD11b+, CD62Lhigh subset of bone marrow derived granulocytes. Int Immunol 2004;16:1675-83.
  34. Wehrhan F, Rödel F, Grabenbauer GG, Amann K, Bruckl W, Schultze-Mosgau S. Transforming growth factor beta 1 dependent regulation of Tenascin-C in radiation impaired wound healing. Radiother Oncol. 2004 Sep;72:297-303.
  35. Schultze-Mosgau S, Lehner B, Rödel F, Wehrhahn F, Amann K, Thorwarth M, Nkenke E, Grabenbauer GG. Expression of Bone Morphogenic Protein (BMP 2/4), Transforming Growth Factor (TGFß1) and Bone Matrix Protein expression in the healing area between vascular tibia grafts and irradiated bone - an experimental model of osteonecrosis. Int J Radiat Oncol Biol Phys 2005;61:1189-96.
  36. Weiss C, Rödel F, Wolf I, Papadopoulos T, Engehausen D, Schrott KM, Sauer R, Rödel C. Combined modality treatment and organ preservation in bladder cancer: Do molecular markers predict outcome. Strahlenther.Onkol 2005;181:213-22.
  37. Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rödel C. Survivin As a Radio-Resistance Factor, and Prognostic and Therapeutic Target for Radiotherapy in Rectal Cancer. Cancer Res 2005;65:4881-87.
  38. Rödel F, Franz S, Sheriff A, Gaipl U, Heyder P, Hildebrandt G, Schultze-Mosgau S, Voll RE, Herrmann M. The CFSE distribution assay is a powerful technique for the analysis of radiation induced cell death and survival on a single cell level. Strahlenther. Onkol 2005;181:456-62.
  39. Schultze-Mosgau S, Kopp J, Thorwarth M, Rödel F, Melnychenko I, Grabenbauer GG, Amann K, Wehrhan F. Plasminogen activator inhibitor-I-related regulation of procollagen I (alpha(1) and alpha(2)) by antitransforming growth factor-beta(1) treatment during radiation-impaired wound healing. Int J Radiat Oncol Biol Phys. 2006;64:280-88.
  40. Baierlein SA, Distel L, Weiss C, Rödel C, Sauer R, Rödel F. Combined effect of Tumor Necrosis Factor-alpha and Ionizing Radiation on the induction of apoptosis in B5637 bladder carcinoma cells. Strahlenther Onkol 2006;182:467-72.
  41. Knauer S, Krämer O, Knösel T, Engels K, Rödel F, Kovács A, Brieger J, Habtemichael N, Hambeck M, Klein-Hitpass L, Rödel C, Mann W, Knecht R, Petersen I, Heinzel T, Stauber R. Nuclear export is essential for the biological activity of survivin – novel aspects to target the survivin pathway in cancer. FASEB Journal 2007;21:207-16.
  42. Weisbach V, Strobel J, Hahn B, Rödel F, Lotter M, Zingsem J, Ringwald J, Eckstein R. Effect of gamma irradiation with 30 Gy on the coagulation  system in WBC-reduced fresh frozen plasma. Transfusion 2007;47:1658-65.
  43. Chen J, Meister S, Urbonaviciute V, Wilhelm S, Rödel F, Manger K, Kalden JR, Voll R. Sensitive detection of plasma/serum DNA in patients with systemic lupus erythematosus. Autoimmunity 2007;40:307-10
  44. Gaipl U, Munoz L, Rödel F, Pausch F , Frey B, Brachvogel B, von der Mark K, Pöschl E. Modulation of the immune system by dying cells and the phosphatidylserine-ligand annexin A5.  Autoimmunity 2007;40:254-59.
  45. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rödel F, Klein-Hitpass L, Kovacs AF, Doring C, Hansmann ML, Hofmann WK, Kunkel M, Brochhausen C, Engels K, Lippert BM, Mann W, Stauber RH. The Survivin Isoform Survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007;6:1502-09.
  46. Ernst-Stecken A, Jeske I, Hess A, Rödel F, Ganslandt O, Grabenbauer GG,, Sauer R, Brune K, Blümke I. Hypofractionated stereotactic radiotherapy to the rat hippocampus. Strahlenther Onkol 2007;183:440-46.
  47. Weiss C, Rödel F, Ott O, Engehausen DG, Papadopoulos T, Sauer R, Rödel C. Pretreatment Proliferation and Local Control in Bladder Cancer after Radiotherapy with or without Concurrent Chemotherapy. Strahlenther Onkol 2007;183:552-556.
  48. Lechler P, Wu X, Bernhardt W, Campean V, Gastiger S, Hackenbeck T, Klanke B, Weidemann A, Warnecke C, Amann K, Engehausen D, Eckardt K, Rödel F, Wiesener M. The tumor gene survivin is highly expressed in adult renal tubular cells – a potential novel mechanism of cellular protection. Am J Pathol 2007;171:1483-98.
  49. Rödel F, Hofmann D, Auer J, Keilholz L, Herrmann M, Röllinghoff M, Sauer R, Beuscher HU. The anti-inflammatory effect of low dose radiation therapy involves a diminished CCL20 chemokine expression and granulocyte/endothelial cell adhesion. Strahlenther Onkol 2008;184:41-47.
  50. Croner RS, Förtsch T, Brückl WM, Rödel F, Rödel C, Papadopoulos T, Brabletz T, Kirchner T, Sachs M, Behrens J, Klein-Hitpass L, Stürzl M, Hohenberger W, Lausen B. Molecular Signature for Lymphatic Metastasis in Colorectal Carcinomas. Ann Surg 2008 ;247:803-10.
  51. Rödel F, Frey B, Leitmann W, Capalbo G, Weiss C, Rödel C. Survivin antisense oligo- nucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys. 2008;71:247-55.
  52. Mantoni T, Schendel R, Rödel F, Niedobitek G, Al-Assar O, Masamune A, Brunner T. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther 2008; 11: 1806-15.
  53. Weiss C, von Römer  F, Capalbo G, Ott O, Wittlinger M, Krause SF, Sauer R, Rödel C, Rödel F. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 2009;74:1455-60.
  54. Frey B, Munoz L, Pausch F, Sieber R, Franz S, Brachvogel B, Pöschl E, Schneider H, Rödel F, Sauer R, Fietkau R, Herrmann M, Gaipl U. The immune reaction against allogeneic necrotic cells is reduced in AnnexinA5 knock out mice whose macrophages display an anti-inflammatory phenotype. J Cell Mol Med 2009,13:1391-99.
  55. Rödel F, Capalbo G, Rödel C, Weiss C. Caveolin-1 as a prognostic marker for local control after preoperative chemoradiation therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2009;73:846-52.
  56. Rödel F, Keilholz L, Herrmann M, Weiss C, Frey B, Voll R, Gaipl U, Rödel C. Activator protein-1 (AP-1) shows a biphasic induction and transcriptional activity after low dose X-irradiation in EA.hy.926 endothelial cells. Autoimmunity 2009; 42: 343-45.
  57. Frey B, Gaipl U, Sarter K, Zaiss M, Stillkrieg W, Rödel F, Schett G, Fietkau R, Keilholz L. The influence of whole body low-dose irradiation on TNF induced arthritis in mice. Autoimmunity 2009; 42:346-48.
  58. Gaipl US, Meister S, Lödermann B, Rödel F, Fietkau R, Herrmann M, Kern PM, and Frey B. Activation-induced cell death and total AKT content of granulocytes shows a biphasic course after low dose irradiation. Autoimmunity 2009; 42: 340-42.
  59. Androic  I, Krämer   A, Yan R, Rödel  F, Gätje  R, Kaufmann M, Strebhardt  K. Yuan Y. Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells  to chemo therapeutics and irradiation. BMC Cancer 2008; 8:391.
  60. Gentner B, Wein A, Croner RS, Zeittraeger I, Wirtz RM, Rödel F, Dimmler A, Dorlaque L, Hohenberger W, Hahn EG, Brueckl W. Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal cancers and their synchronous liver metastases. Anticancer Res 2009;29:67-74.
  61. Frey B, Schildkopf P, Rödel F, Weiss EM, Munoz LE, Herrmann M, Fietkau R, Gaipl US. AnnexinA5 renders dead tumor cells immunogenic-implications for multimodal cancer therapies. J Immunotoxicol 2009;6:209-16.
  62. Capalbo G, Dittmann K , Weiss C, Hausmann E, Rödel C, Rödel F. Radiation-induced survivin nuclear accumulation is linked to DNA damage repair. Int J Radiat Oncol Biol Phys 2010;77:226-34.
  63. Rödel F, Frey B, Capalbo G, Gaipl U, Keilholz L, Voll R, Hildebrandt G, Rödel C. Discontinuous induction of X-linked Inhibitor of Apoptosis in EA.hy.926 endothelial cells is linked to NF-kappaB activation and mediates the anti-inflammatory properties of low-dose ionizing radiation. Radiother Oncol 2010;97:346-51.
  64. Rödel F, Capalbo G, Keppner S, Bashary R, Kaufmann M, Strebhardt K, Rödel C, Spänkuch B. Polo-like Kinase 1 (Plk1) as a prognostic marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol 2010;177:918-29.
  65. Merz F, Merz F, Müller M, Taucher-Scholz G, Rödel F, Stöcker H, Schopow K, Laprell L, Dehghani F, Durante M, Bechmann I. Tissue slice cultures from humans or rodents: a new tool to evaluate biological effects of heavy ions. Radiat Environ Biophys 2010;49:457-62.
  66. Kreis NN, Sanhaji M, Krämer A, Sommer K, Rödel F, Strebhardt K; Juping Yuan J. Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells. Oncogene. 2010;29:5591-603.
  67. Mantel F, Frey B, Haslinger S, Schildkopf P, Sieber R, Ott O, Lödermann B, Rödel F, Sauer R, Fietkau R, Gaipl US. Combination of hyperthermia and ionising irradiation activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells with different radiosensitivities. Strahlenther Onkol 2010;186:587-99.
  68. Weiss E, Frey B, Rödel F, Herrmann M, Voll R, Fietkau R,  Gaipl US.  Ex vivo and in vivo induced dead tumor cells as modulators of anti-tumor responses. Ann NY Acad Sci 2010;1209:109-17.
  69. Sprenger T, Rödel F, Beissbarth T, Conradi L, Rothe  H, Homayounfar K, Wolff H, Ghadimi M, Yildirim M, Becker H, Rödel C, Liersch T. Failure of down-regulation of Survivin expression following neoadjuvant chemoradiation in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 2011;17:1623-31. geteilte Erstautorenschaft.
  70. Berger R, Jennewein C, Marschall V, Karl S, Cristofanon S, Wagner L, Vellanki SH, Hehlgans S, Rödel F, Debatin KM, Ludolph AC, Fulda S. NF-κB is required for Smac mimetic-mediated sensitization of glioblastoma cells for γ-irradiation-induced apoptosis. Mol Cancer Ther, 2011;10:1867-87.
  71. Reichert S, Mirsch J, Tomicic M, Weiss C, Kaina B, Rödel C, Rödel F. Survivin-Inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 2011;101:51-58.
  72. Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, Weber K, Fehse B, Elisabeth Mack E,  Stiewe T, Doerr HW, Speidel D, Cinatl J jr. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug resistant cancer cells. Cell Death Dis. 2011 Dec 15;2:e243. doi: 10.1038/cddis.2011.129.
  73. Reichert S, Reinboldt V, Hehlgans S, Efferth T, Rödel C, Rödel F. A radiosensitizing effect of artesunate in glioblastoma cells is associated with a downregulation of the inhibitor of apoptosis protein survivin. Radiother Oncol 2012;103:394-401.
  74. Lödermann B, Wunderlich R, Frey S, Christine Schorn C, Stangl S, Rödel F, Keilholz L, Fietkau R, Gaipl US, Frey B. Low dose ionising radiation leads to a NF-κB dependent decreased secretion of active IL-1β by activated macrophages in a discontinuous dose-dependency. Int J Radiat Biol 2012;88:727-34.
  75. Moussata D, Amara S, Decaussin M, Mornex  F, Gerard JP, Romestaing P, Rödel F, Flourie B, Benahmed M, Mauduit C. XIAP as a radioresistance factor and  prognostic marker for radiotherapy in human rectal adenocarcinoma. Am J Pathol 2012; 181:1271-8.
  76. Frey B, Stache C, Schulz K, Rubner Y, Sieber R,  Semrau S, Rödel F, Fietkau R, Gaipl US. Chemotherapeutic agents in combination with ionizing irradiation are capable to induce programmed necrosis in colorectal tumor cells and to modulate their in vitro immunogenic potential. J Immunotoxicol 2012;9:301-13
  77. Fraunholz I, Rödel C, Distel L, Kohler D, Falk S, Rödel F. High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy, Radiation Oncology 2012;7:88.
  78. Gaca S, Reichert S, Rödel C, Rödel F, Kreuter J. Anti-Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: preparation, characterisation, drug release, cytotoxicity, and therapeutic effect on colorectal cancer cells. J Microencapsul 2012;29:685-94.
  79. Michaelis M, Rothweiler F, Agha B, Barth S, Voges Y, Löschmann N, von Deimling A, Breitling R, Doerr HW, Rödel F, Speidel D, Cinatl jr. J. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents. Cell Death Dis. 2012;3:e294.
  80. Sprenger T, Conradi L, Beissbarth T, Ermert H, Homayounfar K, Middel P, Rüschoff J, Wolff H, Ghadimi B, Rödel C, Becker H, Rödel F, Liersch T. Enrichment of CD133+ Cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival. Cancer 2013;119:26-35. geteilte Seniorautorschaft.
  81. Frischholz B, Wunderlich R, Rühle  B, Schorn C, Rödel F, Keilholz L, Fietkau R, Gaipl US, Frey B. Reduced secretion of the inflammatory cytokine IL-1β by stimulated peritoneal macrophages of radiosensitive Balb/c mice after exposure to 0.5 or 0.7Gy of ionizing radiation. Autoimmunity 2013;46:323-28.
  82. Fraunholz I, Rödel F, Kohler D, Diallo-Georgiopoulou M, Distel L, Falk S, Rödel C. Epidermal growth factor receptor expression as prognostic marker in patients with anal carcinoma treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2013;86:901-7.
  83. Gaca S, Reichert S, Multhoff G, Hehlgans S, Botzler K, Rödel C, Kreuter J, Rödel F. Targeting and radiosensitization of glioblastoma cells by cmHsp70.1-antibody coated and survivin miRNA plasmid-loaded nanoparticles. J Control Release 2013;172:201-206.
  84. Balermpas P, Michel Y, Wagenblast J, Seitz O, Sipek F, Rödel F, Rödel C, Fokas E. Nuclear NF-kB expression correlates with outcome amongst patients with head and neck squamous cell carcinoma treated with primary chemoradiotherapy. Int J Radiat Oncol Biol Phys 2013;86:785-90
  85. Hehlgans S, Petraki C, Reichert S, Cordes N, Rödel C, Rödel F. Double targeting of Survivin and XIAP radiosensitizes 3D grown human colorectal tumor cells and decreases migration. Radiother Oncol 2013;108:32-39.
  86. Fokas E, Conradi L, Weiss C, Sprenger T, Middel P, Rau  T, Dellas K, Kitz J, Rödel F, Sauer R, Rüschoff J, Beissbarth T, Arnold D, Ghadimi BM, Rödel C, Liersch T. Preoperative radiochemotherapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase-I/II study. Int J Radiat Oncol Biol Phys 2013,87:992-9.
  87. Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rödel F, Rödel C, Fokas E. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014;110:501-9.
  88. Balermpas P, Rödel F, Weiss C, Rödel C, Fokas E. Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. Oncoimmunology 2014;3:e27403.
  89. Large M, Reichert S, Hahlgans S, Fournier C, Rödel C, Rödel F. A non-linear detection of phospho-histone H2AX in EA.hy926 endothelial cells following low-dose X-irradiation is modulated by reactive oxygen species. Radiat Oncol 2014;9:80.
  90. Breuninger S, Erl J, Knape C, Bayer C, Thorsteinsdottir J, Gaipl US, Rödel F, Multhoff G. Quantitative analysis of liposomal Hsp70 in the blood of tumor pateints using a novel lipHsp70 ELISA. J Clin Cell Immunol 2014;5:264.
  91. Wunderlich R, Ernst A, Rödel F, Fietkau R, Ott O, Lauber K, Frey B, Gaipl US. Low and moderate dose of ionising radiation up to 2 Gy modulates transmigration and chemotaxis of activated macrophages, provokes an anti-inflammatory cytokine milieu, but does not impact on viability and phagocytic function. Clin Exp Immunol 2015;179:50-61.
  92. Rödel F, Wieland U, Fraunholz I, Kitz J, Rave Fränk M, Wolff HA, Weiss C, Wirtz R, Heinrichs C, Balermpas P, Fokas E, Rödel C. Human papillomavirus load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer 2015;136:278-88.
  93. Balermpas P, Rödel F, Liberz R, Oppermann J, Wagenblast J, Ghanaati S, Harter PN, Mittelbronn M, Weiss C, Rödel C, Fokas E. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br J Cancer 2015;111:1509-18.
  94. Müller MH, Rödel F, Rüb U, Korf HW. Irradiation with X-rays phase-advances the molecular clockwork in liver, adrenal gland and pancreas. Chronobiol Int. 2015;32:27-36.
  95. Dornoff N, Weiß C, Rödel F, Wagenblast J, Ghanaati S, Atefeh N, Rödel C, Balermpas P. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol 2015;191:656-664.
  96. Large M, Hehlgans S, Reichert S, Gaipl U, Fournier C, Rödel C, Weiss C, Rödel F. Study of the anti-inflammatory effects of low-dose radiation: The contribution of biphasic regulation of the antioxidative system in endothelial cells. Strahlenther Onkol 2015;191:742-749.
  97. Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust K, Limbart D, Rödel F, Wezel F, Haferkamp A, Cinatl J. Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second line therapeutics. Translational Oncology 2015;8:210-216.
  98. Balermpas P, Rödel F, Rödel C, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Gkika E, Stuschke M, Avlar M, Grosu AL, Abdollahi A, Debus J, Bayer C, Stangl S, Belka C, Pigorsch S, Multhoff G, Combs SE, Mönnich D, Zips D, Fokas E; DKTK-ROG. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 2016;48:313-21.
  99. Hehlgans S, Oppermann J, Reichert S, Fulda S, Rödel C, Rödel F. The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. Radiation Oncology 2015;10:198.
  100. Helmke C, Raab M, Rödel F, Matthess Y, Oellerich T, Mandal R, Rödel C, Becker S and Strebhardt K. Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of Caspase-8. Cell Research 2016;26:914-34.
  101. Rödel F, Martin D, Helmke C, Balermpas P, Fokas E, Wieland U, Rave-Fränk M, Kitz J, Matthess Y, Raab M, Strebhardt K, Rödel C. Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. Oncotarget 2016;7:53339-53349.
  102. Voges Y, Michaelis M, Rothweiler F, Schaller T, Schneider C, Politt K, Mernberger M, Nist A, Stiewe T, Rödel F, Cinatl jr. J.  Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance. Cell Death & Disease 2016;7:e2410.
  103. Antonietti P, Linder B, Hehlgans S, Mildenberger I, Burger M, Fulda S, Steinbach J, Gessler F, Rödel F, Mittelbronn M, Kögel D. Interference with the HSF1/HSP70/BAG3 pathway primes glioma cells to matrix detachment and BH3 mimetic-induced apoptosis. Mol Cancer Ther 2017;16:156-168.
  104. Yildirim M, von der Grün J, Winkelmann R, Fokas E, Rödel F, Ackermann H, Rödel C, Balermpas P. Combined p16 and p53 expression in cervical cancer of unknown primary (CUP) and other prognostic parameters: a single center analysis. Strahlenther Onkol 2017;193:205-314.
  105. Balermpas P, Martin D, Wieland U, Rave-Fränk M, Strebhardt K, Rödel C, Fokas E, Rödel F. Human papilloma virus load and PD-1/PD-L1, CD8 and FOXP3 in anal cancer patients treated with chemo radiotherapy: Rationale for immunotherapy. Oncoimmunology 2017 accepted.
  106. Badawi A, Hehlgans S, Pfeilschifter J, Rödel F, Eberhardt W. Silencing of the mRNA-binding protein HuR increases the sensitivity of colorectal cancer cells to ionizing radiation through upregulation of caspase-2. Cancer Letters 2017;393:103-112.
  107. Frey B, Rückert M, Weber J, Mayr X, Derer A, Lotter M, Bert C, Rödel F, Fietkau R, Gaipl US. Hypofractionated irradiation has immune stimulatory potential and induces a timely restricted infiltration of immune cells in colon cancer tumors. Frontiers in Immunol 2017;8:231.
  108. Balermpas P, Rödel F, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Sak A, Stuschke M, Gkika E, Grosu AL, Abdollahi A, Debus J, Stangl S, Ganswindt U, Belka C, Pigorsch S, Multhoff  G, Combs SE, Welz S, Zips D, Lim SY, Rödel C,  Fokas  E.  The PD-1/ PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradio- therapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 2017 epub ahead of print.
  109. Erbeldinger N, Merz F, Ktitareva S, Wendel P, Bothe AS, Dettmering T, Durante M, Friedrich T, Bertulat B, Meyer S, M. Cardoso C, Hehlgans S, Rödel F, Fournier C. Measuring leukocyte adhesion to (primary) endothelial cells after photon and charged particle exposure with a dedicated laminar flow chamber. Frontiers in Immunol 2017;8:627
  110. Wagner J, Pfannenstiel V, Waldmann A, Bergs WJ, Brill B, Hünecke S, Klingebiel T, Rödel F, Buchholz C, Wels W, Peter Bader P, Evelyn Ullrich E.  A two-phase expansion protocol combining IL-15 and IL-21 improves NK cell proliferation and cytotoxicity against Rhabdomyosarcoma. Frontiers in Immunol 2017;8:676.
  111. Rödel F, Steinhäuser K, Nina-Naomi Kreis NN, Friemel A, Martin D, Wieland U, Rave-Fränk M, Balermpas P, Fokas E, Louwen F, Claus Rödel C, Yuan J. Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy.  Radiother Oncol 2017 epub ahead of print.
  112. Martin D, Rödel F, Winkelmann R, Balermpas P, Rödel C, Fokas E. Peripheral leukocytosis is inversely correlated with intratumoral CD8+ T-cell infiltration and associated with worse outcome after chemoradiotherapy in anal cancer. Front Immunol 2017:8;1225.
  113. Stangl S, Tontcheva N, Sievert W, Shevtsov M, Niu M, Pigorsch S, Combs S, Haller B, Balermpas P, Rödel F, Rödel C, Fokas E, Krause M, Linge A, Lohhaus F, Baumann M, Tinhofer I, Budach V, Stuschke M, Grosu AL, Abdollahi A, Debus J, Belka C, Lauber K, Mönnich D, Zips D, Multhoff G. Heat shock protein 70 expression and infiltration of CD56+ NK cells as prognostic indicators of survival in patients with squamous cell carcinoma of the head and neck cancer (SCCHN) after adjuvant radiochemotherapy: a multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 2018;142:1911-25.
  114. Förster S. Hehlgans S, Rödel F, Otto B, Cordes N. Radiochemosensitivity and invasion of human colorectal cancer cells is regulated in an α-catenin-independent manner. Int J Oncol 2018;52:1117-28.
  115. Voos P, Fuck S, Weipert F, Babel L, Tandl D, Spahn A, Hehlgans S, Fournier C, Moronid A, Rödel F, Thiel G. Ionizing radiation induces morphological changes and immunological modulation of Jurkat cells. Front in Immunol 2018:9:922 .
  116. Wunderlich R, Rühle P, Deloch L, Rödel F, Fietkau R, Gaipl U, Frey B. Ionizing radiation reduces the capacity of activated macrophages to induce T-cell proliferation, but does not trigger dendritic cell-mediated non targeted effects. Int J Radiation Biol 2019;95:33-43.
  117. Von der Grün J, Winkelmann R, Meissner  M, Wieland U, Silling S, Martin D, Fokas E, Rödel C, Rödel F, Balermpas P. Merkel cell polyoma viral load and CD8+ lymphocyte infiltration predict overall survival in patients with Merkel cell carcinoma. Front Oncol 2019;9:20.
  118. Diefenhardt M, Hofheinz RD, Martin D, Beissbarth T, Arnold D, Hartmann A, von der Grün J, Grützmann R, Liersch T, Ströbel P, Grabenbauer GG,  Rieger M, Fietkau R, Graeven U, Weitz J, Folprecht G, Ghadimi M, Rödel F, Rödel C, Fokas E. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. Int J Cancer 2019; epub ahead of print.
  119. Linder B, Wehle A, Bonn F, Hehlgans S, Dikic I, Rödel F. Seifert V, Kögel D. Arsenic Trioxid and (-)-Gossypol) synergistically target glioma stem-like cells via Inhibition of Hedgehog and Notch signaling. Cancers 2019;11:350.
  120. Raab M, Sanhaji M, Zhou S, Rödel F, El-Balat A, Becker S, Strebhardt K. Blocking mitotic exit of ovarian cancer cells by pharmaceutical inhibition of the Anaphase-Promoting Complex reduces chromosomal instability. Neoplasia 2019;21:363-375.
  121. Müller-Längle A, Lutz H, Hehlgans S, Rödel F, Rau K, Laube B. NMDA Receptor-mediated signaling pathways enhance radiation resistance, survival and migration in glioblastoma cells - a potential target for adjuvant radiotherapy. Cancers 2019;11:350.
  122. Fleischmann M, Martin D, Peña-Llopis S, Oppermann J, von der Grün J, Diefenhardt M, Chatzikonstantinou G, Fokas E, Rödel C, Strebhardt K, Becker S, Rödel F, Tselis N. Association of Polo-like kinase 3 and phosphoT273 Caspase 8 with improved survival in patients with cervical squamous cell carcinoma treated with radical chemoradiotherapy and brachytherapy. Front Oncol 2019,9:742
  123. Feczkó T, Piiper A, Pleli T, Schmithals C, Denk D, Hehlgans S, Rödel F, Vogl TJ, Wacker MG. Theranostic sorafenib-loaded polymeric nanocarriers manufactured by enhanced gadolinium conjugation techniques. Pharmaceutics 2019,11:489.
  124. Martin D, Rödel F, Balermpas P, Winkelmann R, Fokas E, Rödel C. C-reactive protein-to-albumin ratio as prognostic marker for anal squamous cell carcinoma treated with chemoradiotherapy. Front Oncol 2019 accepeted.
  125. Chae W, Schulz M, Niesel K, Klemm F, Joyce J, Prümmer M, Brill B, Bergs J, Rödel F, Pilatus U, Sevenich L. Evaluating therapeutic response of whole brain radiotherapy in a mouse model for breast-to-brain metastasis using magnetic resonance imaging and spectroscopy. Front Oncol 2019;9:1324.
  126. Michaelis M, Voges Y, Rothweiler F, Weipert F, von Deimling A, Westermann F, Rödel F, Wassa M, Cinatl J. Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines. Cancers 2020;12:E577.
  127. Michaelis M, Wass M, Reddin I, Voges Y, Rothweiler F, Hehlgans S, Mernberger M, Nist A, Stiewe T, Rödel F, Cinatl J. Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of specific biomarkers for the acquired resistance setting, Cancers 2020;12:E1080.
  128. Martin D, Rödel F, von der Grün J, Rödel C, Fokas E. Acute organ toxicity correlates with better clinical outcome after chemoradiotherapy in patients with anal carcinoma. Radiother Oncol 2020;149:168-173.
  129. Freund I, Hehlgans S, Martin D, Ensminger M, Fokas E, Claus Rödel C, Löbrich M, Rödel F. Fractionation-dependent radiosensitization by molecular targeting of Nek1. Cells 2020;9:E1235.
  130. Schulz M, Michels B, Niesel K, Stein S, Farin H, Rödel F, Sevenich L. Cellular and molecular changes of brain metastases-associated myeloid cells during disease progression and therapeutic response. iScience 2020;23:101178.
  131. Kesar N, Winkelmann R, Oppermann J, Ghanaati S, Neumayer T, Martin D, Rödel C, Rödel F, von der Grün J, Balermpas P. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. Oral Oncology 2020;111:10493.
  132. Rödel F, Zhou S, Győrffy B, Raab M, Sanhaji M, Mandal R, Becker S, Strebhardt K. The prognostic relevance of the proliferation markers Ki-67 and Plk1 in early-stage ovarian cancer patients with serous, low-grade carcinoma based on mRNA and protein expression. Front Oncol 2020;10:558932.
  133. Güllülü Ö, Hehlgans S, Mayer BE, Gößner I, Petraki C, Hoffmann M, Dombrowsky MJ, Kunzmann P, Hamacher K, Strebhardt K, Fokas E, Rödel C, Münch C, Rödel F. A spatial and functional interaction of a heterotetramer Survivin-DNA-PKcs complex in DNA damage response. Cancer Res 2021;81:2304-2317.
  134. Von der Grün J, Winkelmann R, Rödel F, Balster S, Ghanaati S, Brandts C, Martin D, Rödel C, Kesar N, Balermpas P. Patterns of care, toxicity and outcome after treatment of salivary gland carcinomas: Long-term experience from a tertiary cancer center. Eur Arch Oto-Rhino-L 2021;278:4411-4421.
  135. Niesel K, Schulz M, Anthes J, Alekseeva T, Macas J, Salamero-Boix A, Möckl A, Oberwahrenbrock T, Lolies M, Stein S, Plate KH, Reiss Y, Rödel F, Sevenich L. The immune suppressive microenvironment affects efficacy of radio-immunotherapy in brain metastasis. EMBO Mol Med 2021:13:e1341.
  136. Altay-Langguth A, Balermpas P, Brandts C, Balster S, Ghanaati S, Winkelmann R, Burck I, Rödel F, Martin D, Rödel C, von der Grün J. Re-irradiation with concurrent and maintenance Nivolumab in locally recurrent and inoperable Squamous Cell Carcinoma of the Head and Neck: a single-center cohort study. Clin Transl Radiat Oncol 2021;28:71-78.
  137. Linder B, Schiesl A, Voss M, Rödel F, Hehlgans S, Güllülü Ö, Seifert V, Kögel D, Senft C, Dubinski D. Dexamethasone treatment limits efficacy of radiation, but does not interfere with glioma cell death induced by Tumor Treating Fields. Front Oncol 2021;11:715031.
  138. Niu M, Combs SE, Linge A, Krause M, Baumann M, Lohaus F, Ebert N, Tinhofer I, Budach V, von der Grün J, Rödel F, Grosu AL, Multhoff G. Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiat Oncol 2021;16:141.
  139. Eckert D, Rapp F, Tsedeke AT, Molendowska J, Lehn R, Langhans M, Fournier C, Rödel F, Hehlgans S. ROS- and Radiation Source-Dependent Modulation of Leukocyte Adhesion to Primary Microvascular Endothelial Cells. Cells 2022;11:72.
  140. Nicolas A, Pesic M, Engel E, Paul K. Ziegler P, Diefenhardt M, Kennel KB, Büttner F, Conche C, Petrocelli V, Elwakeel E, Weigert A, Zinoveva A, Fleischmann M, Häupl B, Karakütük C, Bohnenberger H, Mosa M, Kaderali L, Gaedcke J, Ghadimi M, Rödel F, Arkan MC, Oellerich T, Rödel C, Fokas E, Greten FR. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell 2022;40:1-17.
  141. Deloch L, Hehlgans S, Rückert M, Maier A, Hinrichs A, Flohr AS, Eckert D, Weissmann T, Seeling M, Nimmerjahn F, Fietkau R, Rödel F, Fournier C, Frey B, Gaipl US. Radon improves clinical response in an animal model of rheumatoid arthritis accompanied by increased numbers of peripheral blood B cells and Interleukin-5 concentration. Cells 2022;11:689.
  142. Tandl D, Sponagel T, Fuck S, Smit T, Hehlgans S, Jacob B, Fournier C. Rödel F, Roth B, Moroni A, Alansary D, Niemeyer B, Thiel G. X-ray irradiation activates immune response in human T-lymphocytes via store-operated Ca2+ entry and NFAT activation. J Gen Physiol 2022;154:e202112865.
  143. Von Der Grün J, Winkelmann R, Burck I, Martin D, Rödel F, Wild PJ, Bankov K, Weigert A, Kur IM, Brandts C, Filmann N, Issing C, Thönissen P, Tanneberger AM, Rödel C, Ghanaati S, Balermpas P. Neoadjuvant chemoradiotherapy for oral cavity cancer: Predictive factors for response and interim analysis of the prospective INVERT-Trial. Front Oncol 2022;12:817692
  144. Mandal R, Raab M, Rödel F, Krämer A, Kostova I, Peňa-Llopis S, Häupl B, Oellerich T, Gasimli K, Sanhaji M, Becker S, Strebhardt K. The non-apoptotic function of Caspase-8 in negatively regulating the CDK9 mediated Ser2 phosphorylation of RNA Polymerase II in cervical cancer. Cell Mol Life Sci 2022;79:597.
  145. Fleischmann M, Mandal R, Kostova I, Raab M, Sanhaji M, Hehlgans S, Diefenhardt, Fokas E, Rödel C, Strebhardt K. Rödel F. Prognostic impact of caspase-8, CDK9 and phospho-CDK9 (Thr 186) expression in patients with uterine cervical cancer treated with definitive chemoradiation and brachytherapy. Cancers 2022;14:550.
  146. Berglar I, Hehlgans S, Wehle A, Roth C, Herold-Mende C, Rödel F, Kögel D, Linder B. CHRDL1 regulates stemness in glioma stem-like cells. Cells 2022;11:3917.
  147. Burger MC, Forster MT, Romanski A, Straßheimer F, Macas J, Zeiner PS, Steidl E, Herkt S, Weber KJ, Schupp J, Lun JH, Strecker MI, Wlotzka K, Cakmak P, Opitz C, George R, Mildenberger IC, Nowakowska P, Zhang C, Röder J, Müller E, Ihrig K, Langen KJ, Rieger MA, Herrmann E, Bönig H, Harter PN, Reiss Y, Hattingen E, Rödel F, Plate KH, Tonn T, Senft C, Steinbach JP, Wels WS. Intracranial injection of NK cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol 2;25:2058-2071.

  148. Martin D, Rödel F, Hehlgans S, Looso M, Ziegler PK, Fleischmann M, Diefenhardt M, Fries L, Kalinauskaite G, Tinhofer I, Zips D, Gani C, Rödel C, Fokas E. Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma. NPJ Precis Oncol 2024;8(1):93. 

  149. Hehlgans S, Eckert D, Martin D, Lumniczky K, Bug G, Rödel C, Rödel F. Irradiation alters extracellular vesicle microRNA load in the serum of patients with leukaemia. Strahlenther Onkol 2024 accepted.

Übersichtsarbeiten/Reviews/Kommentare

  1. Rödel F, Kamprad F, Sauer R, Hildebrandt G. Funktionelle und molekulare Aspekte der antiinflammatorischen Wirkung niedrig dosierter Radiotherapie. Strahlenther Onkol 2002;178:1-9.
  2. Munoz L, Frey B, Pausch F, Baum W, Brachvogel B, Pöschl E, Rödel F, von der Mark K, Herrmann M, Gaipl U. The role of annexin A5 in the modulation of the immune response against dying and dead cells. Review Curr Med Chem 2007;14:271-77.
  3. Rödel F, Keilholz L, Herrmann M.; Sauer R, Hildebrandt G. Radiobiological mechanisms in inflammatory diseases of low dose radiation therapy. Int J Radiat Biol 2007;83:357-66.
  4. Capalbo G, Rödel C, Stauber RH, Knauer SK, Bache M, Kappler M, Rödel F. The Role of Survivin for radiation therapy: prognostic and predictive factor and therapeutic target. Strahlenther Onkol 2007;183:593-99.
  5. Marquardt F, Rödel F, Capalbo G, Weiss C, Rödel C. Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 2009; 185: 371-378.
  6. Rödel F, Reichert S, Sprenger T, Gaipl US, Mirsch J, Liersch T , Fulda S, Rödel C. The role of survivin for radiation oncology: moving beyond apoptosis Inhibition. Curr Med Chem  2011;18:191-99.
  7. Rödel F, Frey B, Gaipl U, Keilholz L, Fournier C, Manda K, Schöllnberger H, Hildebrandt G, Rödel C. Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular Mechanisms and clinical application. Curr Med Chem 2012;19:1741-50.
  8. Rödel F , Sprenger T,  Kaina B, Liersch T, Rödel C., Fulda S, Hehlgans S. Survivin as a prognostic/predictive molecular maker and therapeutic target in cancer therapy. Curr Med Chem 2012,19,3679-88.
  9. Rodemann HP, Rödel F, Cordes N. Molekulare Signalwege: Mechanismen und klinische Anwendung. Strahlenther Onkol 2012;188 Suppl. 3:308-11.
  10. Rödel F., Frey B, Manda K, Hildebrandt G, Hehlgans S, Keilholz L, Seegenschmidt MH, Gaipl U, Rödel C. Immunomodulatory Properties and Molecular Effects in Inflammatory Diseases of Low-dose X-Irradiation. Front Oncol 2012;2:120. 
  11. Heylmann D, Rödel F, Kindler T, Kaina B. Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells. Biochim Biophys Acta 2014 ;1846:121-129.
  12. Gaipl US, Multhoff G, Scheithauer H, Lauber K, Hehlgans S, Frey B, Rödel F. Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy 2014 ;6:597-610.
  13. Rödel F, Frey B, Multhoff G, Gaipl U. Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett 2015;356:105-13.
  14. Specht H, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl U, Günther C, Gunther S,  Habl G, Hautmann H, Hautmann M, Huber R, Molls M, Offner R, Rödel C, Rödel F, Schuetz M, Combs S, Multhoff G. Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy – from preclinical studies to a clinical phase II trial. Front Immunol 2015;6:162.
  15. Frey B, Hehlgans S, Rödel F, Gaipl US. Modulation of inflammation by low and high doses of ionizing radiation: Implications for benign and malign diseases. Cancer Lett  2015;368:230-37.
  16. Reichl B, Block A, Schäfer U, Bert C, Müller R, Jung H, Rödel F, German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD). DEGRO practical guidelines for radiotherapy of non-malignant disorders: Part I: physical principles, radiobiological mechanisms, and radiogenic risk. Strahlenther Onkol 2015;191:701-709.
  17. Bergs J, Wacker M, Hehlgans S, Piiper A, Multhoff G, Rödel C, Rödel F. The role of recent nanotechnology in enhancing the efficacy of radiation therapy. Biochim Biophys Acta 2015;1856:130-143.
  18. Rödel F, Balermpas P. Anti-epidermal growth factor receptor immunotherapy in combination with cisplatin chemoradiation for patients with advanced head and neck carcinoma-biological and clinical limitations of the triple treatment. Transl Cancer Res 2016;5:199-202.
  19. Rödel F, Fournier C, Wiedemann J, Merz F, Gaipl US, Frey B, Keilholz L, Seegenschmiedt MH, Rödel C, Hehlgans S. Basics of radiation biology when treating hyperproliferative benign diseases. Frontiers in Immunol 2017;8:519.
  20. Martin D, Rödel F,  Balermpas P, Rödel C, Fokas E. The immune microenvironment in the context of HPV in anal cancer: Rationale for immunotherapy. Biochim Biophys Acta  2017;1868:221-230.
  21. Martin D, Balermpas P, Winkelmann R, Rödel F, Rödel C, Fokas E. Anal squamous cell carcinoma – State of the art management and future perspectives. Cancer Treat Rev 2018;65:11-21.
  22. Rödel F, Martin D, Balermpas P, Wieland U, Winkelmann R, Riekmann T, Falk S, Rödel C, Fokas E. Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. Biochim Biophys Acta Rev Cancer  2019;1871:126-137.
  23. Montero A, Sabater S, Rödel F, Gaipl US, Ott OJ, Seegenschmiedt MH, Arenas M. Is it time to redefine the role of low-dose radiotherapy for benign disease? Ann Rheum Dis 2018 Comment, epub ahead of print.
  24. Ott OJ, Micke O, Mücke R, Niewald M, Rödel F, Schäfer U, Seegenschmiedt MH, Arenas M, Frey B, Gaipl US. Low-dose radiotherapy: Mayday, mayday, we've been hit! Strahlenther Onkol. 2019 ;195:285-288.
  25. Von der Grün J, Rödel F, Fokas E, Guckenberger M, Rödel C, Brandts C, Balermpas P. Targeted therapies and immune-checkpoint inhibition in head and neck squamous cell carcinoma: Where do we stand and where to go. Cancers 2019;11:472.
  26. Gaipl U, Multhoff G, Pockley G, Rödel F.  Editorial: Radioimmunotherapy—Translational Opportunities and Challenges. Front Oncol 2020;10:190.
  27. Rödel F, Arenas M, Ott O, Fournier C, Georgakilas AG, Tapio S, Trott KR, Gaipl US. Low-dose radiation therapy for COVID-19 pneumopathy: What are the evidences? Strahlenther Onkol 2020;196-682.
  28. Lumniczky K, Impens N, Armengol G, Candéias S, Georgakilas A, Hornhardt S, Martin O, Rödel F, Schaue D. Low dose ionizing radiation effects on the immune system. Environment Intern 2021:149:06212.
  29. Maier A, Wiedemann J, Rapp F, Papenfuß F, Rödel F, Hehlgans S, Udo S. Gaipl US, Kraft G,  Fournier C, Frey B. Radon exposure – therapeutic effect and cancer risk. Int J Mol Sci 2021;22:316.
  30. Güllülü Ö, Hehlgans S, Rödel C, Fokas E, Rödel F. Tumor suppressor protein p53 and inhibitor of apoptosis proteins in colorectal cancer – a promising signalling network for therapeutic interventions. Cancers 2021;13:624.
  31. Obermüller T, Hautekiet J, Paula Busto M, Reynders D, Belgioia L, Cats A, Gilbert D, Koerber SA, Mai S, Meulendijks D, Rödel F, Yhim HY, Hetjens S, Weiß C, Rasmussen C, Urbute A, Verdoot F, Kjaer S, Reuschenbach M, Goetghebeur E, von Knebel Doeberitz M, Arbyn M, Prigge ES. Prognostic value of high-risk HPV DNA and p16INK4a immunohistochemistry in anal cancer patients: an individual patient data meta-analysis. Eur J Cancer 2021;157:165-178
  32. Fleischmann M, Chatzikonstantinou G, Fokas E, Wichmann J, Hans Christiansen H, Klaus Strebhardt K, Rödel C, Tselis N, Rödel F. Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. Cancers 2021;13:5748.
  33. Fleischmann M, Nicolas AM, Rödel F, Ghadimi M, Hofheinz RD, Greten FR, Rödel C, Fokas E. ACO/ARO/AIO-21 - Capecitabine-based Chemoradiotherapy in Combination with the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients: A Phase I Trial of the German Rectal Cancer Study Group. Clin Transl Radiat Oncol 2022;34:99-106.
  34. George R, Hehlgans S, Fleischmann M, Rödel C, Fokas E, Rödel F. Advances in nanotechnology-based platforms for survivin-targeted drug discovery. Expert Opin Drug Discov 2022;17:733-754.
  35. Nicolas A, Pesic M, Rödel F, Fokas E, Greten FR. Preclinical orthotopic mouse model of rectal cancer and neoadjuvant therapy. STAR Protocol (Cell Press) 2022;3:101749.
  36. Viktorsson K, Rieckmann T, Fleischmann M, Diefenhardt M, Hehlgans S, Rödel F. Advances in Molecular Targeted Therapies to Increase Efficacy of (Chemo)Radiation Therapy. Strahlenther Onkol 2023;199:1091-1109.

Buchbeiträge

  1. Rödel F, Rödel C, Sauer R. Apoptosis as a predictive marker for response to neoadjuvant radiochemotherapy in patients with rectal cancer. In Kogelnik HD, Lukas P, Sedlmayer T. Progress in Radiooncology VII. Monduzzi Editore, Bologna Italy 2002;517-523.
  2. Rödel F, Seegenschmiedt M.H. Introduction to radiation biology when treating hyperproliferative benign diseases.  in Werker P.M.N, Dias J, Reichert B , Wach W. Dupuytren Disease and Related Diseases – The Cutting Edge. Springer Verlag 2016;333-339.
MENÜ